In vivo, the mice with the synergistic therapy showed greater tumor growth inhibition and significantly fewer pulmonary metastatic nodules than that of the control mice by promoting the proliferation and infiltration of CD8+ T cells in the TME and suppressing the transcript of PD-L1 (166). The gene discussed is CD8A; the disease is neoplasm.